For advanced prostate cancer, new drug slows disease

Med-Chemist ― In continuation of my update on abirateroneThe study is the first randomized clinical trial to document expanded benefits among a particular group of prostate cancer patients in whom the disease had spread. The medication, abiraterone acetate -- marketed as Zytiga -- also delayed the development of pain and deterioration of the patients' overall condition.The researchers say the medication could provide new treatment options."This drug extended lives and gave patients more time when they weren't [...].